Verona Pharma Plc ADR (NASDAQ: VRNA) has seen a rise in its stock price by 2.00 in relation to its previous close of 38.09. However, the company has experienced a 5.20% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-19 that LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024:
Is It Worth Investing in Verona Pharma Plc ADR (NASDAQ: VRNA) Right Now?
The 36-month beta value for VRNA is also noteworthy at 0.45. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VRNA is 68.82M, and at present, short sellers hold a 10.93% of that float. The average trading volume of VRNA on November 21, 2024 was 1.02M shares.
VRNA’s Market Performance
VRNA’s stock has seen a 5.20% increase for the week, with a 11.41% rise in the past month and a 43.62% gain in the past quarter. The volatility ratio for the week is 5.92%, and the volatility levels for the past 30 days are at 5.38% for Verona Pharma Plc ADR The simple moving average for the past 20 days is 6.76% for VRNA’s stock, with a 77.52% simple moving average for the past 200 days.
Analysts’ Opinion of VRNA
Many brokerage firms have already submitted their reports for VRNA stocks, with Wells Fargo repeating the rating for VRNA by listing it as a “Overweight.” The predicted price for VRNA in the upcoming period, according to Wells Fargo is $50 based on the research report published on October 03, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see VRNA reach a price target of $38, previously predicting the price at $35. The rating they have provided for VRNA stocks is “Buy” according to the report published on May 22nd, 2023.
Wedbush gave a rating of “Outperform” to VRNA, setting the target price at $27 in the report published on September 19th of the previous year.
VRNA Trading at 16.68% from the 50-Day Moving Average
After a stumble in the market that brought VRNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.19% of loss for the given period.
Volatility was left at 5.38%, however, over the last 30 days, the volatility rate increased by 5.92%, as shares surge +11.22% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +28.86% upper at present.
During the last 5 trading sessions, VRNA rose by +5.20%, which changed the moving average for the period of 200-days by +126.00% in comparison to the 20-day moving average, which settled at $36.39. In addition, Verona Pharma Plc ADR saw 95.42% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRNA starting from EBSWORTH DAVID R, who purchase 20,000 shares at the price of $4.44 back on Nov 18 ’24. After this action, EBSWORTH DAVID R now owns 940,003 shares of Verona Pharma Plc ADR, valued at $88,800 using the latest closing price.
ZACCARDELLI DAVID, the President and CEO of Verona Pharma Plc ADR, sale 2,400 shares at $5.00 during a trade that took place back on Nov 11 ’24, which means that ZACCARDELLI DAVID is holding 15,202,352 shares at $12,000 based on the most recent closing price.
Stock Fundamentals for VRNA
Current profitability levels for the company are sitting at:
- -23.71 for the present operating margin
- 0.8 for the gross margin
The net margin for Verona Pharma Plc ADR stands at -23.45. The total capital return value is set at -0.44. Equity return is now at value -78.35, with -45.78 for asset returns.
Based on Verona Pharma Plc ADR (VRNA), the company’s capital structure generated 0.48 points at debt to capital in total, while cash flow to debt ratio is standing at -0.86. The debt to equity ratio resting at 0.93. The interest coverage ratio of the stock is -11.23.
Currently, EBITDA for the company is -52.47 million with net debt to EBITDA at 1.71. When we switch over and look at the enterprise to sales, we see a ratio of 451.77. The receivables turnover for the company is 0.39for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.03.
Conclusion
In summary, Verona Pharma Plc ADR (VRNA) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
